The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics
The DOI matches its Crossref record; 157 of the 157 references it cites were found in a registry or an index.
Abstract
The amyloid cascade hypothesis, which posits that the deposition of the amyloid-β peptide in the brain is a central event in Alzheimer's disease pathology, has dominated research for the past twenty years. Several therapeutics that were purported to reduce amyloid-β production or aggregation have failed in Phase III clinical testing, and many others are in various stages of development. Therefore, it is timely to review the science underpinning the amyloid cascade hypothesis, consider what type of clinical trials will constitute a valid test of this hypothesis and explore whether amyloid-β-directed therapeutics will provide the medicines that are urgently needed by society for treating this devastating disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Pathogenetic studies have shown that Aβ peptide accumulation in the brain is an early and central event, 2”
From Amyloid Plaque Imaging with a Targeted MRI Contrast Agent in a Transgenic Mouse Model of Alzheimer’s Disease (2022) · cites this paper as [2]
In the citing paper
“One possible resolution is that amyloid pathology acts only as a trigger in sporadic AD (Karran et al., 2011); i.e., Aβ accumulation is necessary but insufficient to cause full-blown disease.”
From The Major Risk Factors for Alzheimer’s Disease: Age, Sex, and Genes Modulate the Microglia Response to Aβ Plaques (2019) · cites this paper as Karran et al., 2011
In the citing paper
“since it is known that the Aβ plaques act as a driver of AD pathology63 and the accumulation Aβ plaques in the brain initiates a complex multicellular neurodegenerative process.”
From Interferon signaling modulates Down syndrome-associated Alzheimer’s disease pathology in a mouse model (2025) · cites this paper as [63]
In the citing paper
“The amyloid cascade hypothesis, which dominated the field for over three decades, proposed that the abnormal accumulation of Aβ initiates a downstream cascade leading to tau hyperphosphorylation, synaptic dysfunction, and neuronal death [6, 7].”
From Toward a Unified Framework in Molecular Neurobiology of Alzheimer’s Disease: Revisiting the Pathophysiological Hypotheses (2026) · cites this paper as [7]
In the citing paper
“a possible cause of clinical failure could be the difficulty of inhibiting these proteinases without causing side effects resulting from non-targeted proteolytic inhibition on their many physiological substrates”
From Emerging Alternative Proteinases in APP Metabolism and Alzheimer’s Disease Pathogenesis: A Focus on MT1-MMP and MT5-MMP (2019) · cites this paper as Karran et al., 2011
6 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
1 retracted
RETRACTED ARTICLE: A specific amyloid-β protein assembly in the brain impairs memory
Lesné, S., Koh, M. T., Kotilinek, L., Kayed, R., Glabe, C. G., Yang, A., Gallagher, M., & Ashe, K. H. (2006) · Nature · doi:10.1038/nature04533 · Cited by 2,769
RetractedMcKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123
The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
The Clinical Dementia Rating (CDR): Current version and scoring rules
Morris, J. C. (1993) · Neurology · doi:10.1212/wnl.43.11.2412-a · Cited by 9,882
Corder, E. H., Saunders, A. M., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Small, G. W., Roses, A. D., Haines, J. L., & Pericak-Vance, M. A. (1993) · Science · doi:10.1126/science.8346443 · Cited by 9,429 · cited 1×
“The apolipoprotein E ( APOE ) gene represents the major genetic risk factor for A”
BackgroundAlzheimer's disease: the amyloid cascade hypothesis
Hardy, J. A., & Higgins, G. A. (1992) · Science · doi:10.1126/science.1566067 · Cited by 7,484
Sperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, C. R., Kaye, J., Montine, T. J., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.003 · Cited by 7,155
Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade
Jack, C. R., Knopman, D. S., Jagust, W. J., Shaw, L. M., Aisen, P. S., Weiner, M. W., Petersen, R. C., & Trojanowski, J. Q. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70299-6 · Cited by 4,806
Goate, A., Chartier-Harlin, M.-C., Mullan, M., Brown, J., Crawford, F., Fidani, L., Giuffra, L., Haynes, A., Irving, N., James, L., et al. (1991) · Nature · doi:10.1038/349704a0 · Cited by 4,659 · cited 1×
“The discovery that AD could be inherited in an autosomal dominant fashio”
Background
Research works printed but not linked: 2
- Burns, A. & Ilife, S. Dementia. BMJ 338, 405–409 (2009).
- Alzheimer, A. About a peculiar disease of the cerebral cortex. [in German] Centralblatt für Nervenheilkunde Psychiatrie 30, 177–179 (1907).
Cited by
Items 501–600 of 1,007
The Role of Glial Cells in Synaptic Dysfunction: Insights into Alzheimer's Disease Mechanisms
Yu, Y., Chen, R., Mao, K., Deng, M., & Li, Z. (2023) · Aging and Disease · doi:10.14336/ad.2023.0718 · Cited by 66
“Despite numerous drugs being tested in animal models and phase II/III clinical trials, most have failed to produce positive results [4].”
BackgroundHunt, K. W., Cook, A. W., Watts, R. J., Clark, C. T., Vigers, G. P. A., Smith, D. J., Metcalf, A. T., Gunawardana, I. W. K., Burkard, M., Cox, A., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm4002154 · Cited by 63
SIRT1 as a therapeutic target for Alzheimer’s disease
Wong, S. Y., & Tang, B. L. (2016) · Reviews in the Neurosciences · doi:10.1515/revneuro-2016-0023 · Cited by 61
Kumar, A., Tiwari, A. K., & Sharma, A. K. (2018) · Current Neuropharmacology · doi:10.2174/1570159x16666180315141643 · Cited by 69
“Aβ aggregation inhibitors Amyloid peptide [6] Amyloid fibril [15]”
BackgroundSamanta, S., Rajasekhar, K., Babagond, V., & Govindaraju, T. (2019) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.9b00216 · Cited by 59
Cai, X., Zhang, K., Xie, X., Zhu, X., Feng, J., Jin, Z., Zhang, H., Tian, M., & Chen, H. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2019.119678 · Cited by 60
Mapping the multicausality of Alzheimer’s disease through group model building
Uleman, J. F., Melis, R. J. F., Quax, R., van der Zee, E. A., Thijssen, D. H. J., Dresler, M., van de Rest, O., van der Velpen, I. F., Adams, H. H. H., Schmand, B. A., et al. (2020) · GeroScience · doi:10.1007/s11357-020-00228-7 · Cited by 68
“Furthermore, clinical trials based on this hypothesis have not yet yielded effective disease-modifying treatments (Cummings et al. 2019; Karran et al. 2011).”
Shao, X., Carpenter, G. M., Desmond, T. J., Sherman, P. S., Quesada, C., Fawaz, M. V., Brooks, A. F., Kilbourn, M. R., Albin, R. L., Frey, K. A., et al. (2012) · ACS Medicinal Chemistry Letters · doi:10.1021/ml300216t · Cited by 63
Broadstock, M., Ballard, C., & Corbett, A. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2014.936848 · Cited by 58
“The precise disease mechanisms in AD remain unclear, and there is some controversy regarding the role of specific toxic substrates [2].”
BackgroundCerebrospinal fluid ratios with Aβ42 predict preclinical brain β‐amyloid accumulation
Racine, A. M., Koscik, R. L., Nicholas, C. R., Clark, L. R., Okonkwo, O. C., Oh, J. M., Hillmer, A. T., Murali, D., Barnhart, T. E., Betthauser, T. J., et al. (2016) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · doi:10.1016/j.dadm.2015.11.006 · Cited by 58
“The most widely accepted model of AD etiology proposes that amyloid deposition in the brain is an early and critical step in driving the pathophysiological processes of AD that in turn initiate neurodegeneration, in the form of synaptic failure and neuronal death, and eventual symptom manifestation [1,6,7].”
BackgroundAtomic Details of the Interactions of Glycosaminoglycans with Amyloid-β Fibrils
Stewart, K. L., Hughes, E., Yates, E. A., Akien, G. R., Huang, T., de Lima, M. A., Rudd, T. R., Guerrini, M., Hung, S., Radford, S. E., et al. (2016) · Journal of the American Chemical Society · doi:10.1021/jacs.6b02816 · Cited by 59
Banerjee, S., Hashemi, M., Lv, Z., Maity, S., Rochet, J., & Lyubchenko, Y. L. (2017) · Scientific Reports · doi:10.1038/srep45592 · Cited by 58
Moonga, I., Niccolini, F., Wilson, H., Pagano, G., Politis, M., & Initiative, T. A. D. N. (2017) · European Journal of Neurology · doi:10.1111/ene.13374 · Cited by 61
“The cardinal pathology in AD includes accumulation of extracellular amyloid-b (Ab) plaques and intracellular neurofibrillary tangles of hyperphosphorylated tau, as well as synaptic loss [2].”
BackgroundChen, K., Lu, Y., Liu, C., Zhang, L., Fang, Z., & Yu, G. (2018) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2018.07.047 · Cited by 57
Wesenhagen, K. E. J., Teunissen, C. E., Visser, P. J., & Tijms, B. M. (2020) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408363.2019.1670613 · Cited by 57
Chidambaram, H., Das, R. R., & Chinnathambi, S. (2022) · European Journal of Cell Biology · doi:10.1016/j.ejcb.2022.151201 · Cited by 59
Cyclodextrins: Only Pharmaceutical Excipients or Full-Fledged Drug Candidates?
Kovács, T., Nagy, P., Panyi, G., Szente, L., Varga, Z., & Zákány, F. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14122559 · Cited by 69
“Alzheimer’s disease is the most common neurodegenerative disorder that eventually leads to progressive dementia and it is casually linked to the extracellular deposition of aggregated fibrils built up by Aβ peptides [172,173].”
BackgroundLiao, K., Chen, K., Lee, W., Sun, M.-F., Lee, C.-C., & Chen, C. Y. (2014) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2014/364819 · Cited by 63
“In recent years, most beta-amyloid-centric drug developments have been unsuccessful during Phase III of clinical trials [27, 28].”
BackgroundSmid, S. D., Maag, J. L., & Musgrave, I. F. (2012) · Food & Function · doi:10.1039/c2fo30075c · Cited by 57
Lai, J., Mei, Z. L., Wang, H., Hu, M. Y., Long, Y., Miao, M. X., Li, N., & Hong, H. (2014) · Neurochemistry International · doi:10.1016/j.neuint.2014.05.006 · Cited by 60
“In the amyloid cascade hypothesis for AD, Ab, particularly the Ab1–42 isoform, plays an early and crucial role in the pathogenesis of the disease (Karran et al., 2011).”
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and Alzheimer's disease
Kadmiri, N. E., Slassi, I., Moutawakil, B. E., Nadifi, S., Tadevosyan, A., Hachem, A., & Soukri, A. (2014) · Pathologie Biologie · doi:10.1016/j.patbio.2014.08.002 · Cited by 58
“hyperphosphorylated tau) [2–4].”
Protein aggregation, misfolding and consequential human neurodegenerative diseases
Sami, N., Rahman, S., Kumar, V., Zaidi, S., Islam, A., Ali, S., Ahmad, F., & Hassan, M. I. (2017) · International Journal of Neuroscience · doi:10.1080/00207454.2017.1286339 · Cited by 64
Singh, A. K., Bissoyi, A., Kashyap, M. P., Patra, P. K., & Rizvi, S. I. (2017) · Neurotoxicity Research · doi:10.1007/s12640-017-9746-5 · Cited by 57
Ferroptosis Is Regulated by Mitochondria in Neurodegenerative Diseases
Zhou, J.-P., Jin, Y., Lei, Y.-H., Liu, T., Wan, Z., Meng, H., & Wang, H. (2020) · Neurodegenerative Diseases · doi:10.1159/000510083 · Cited by 59
Ferroptosis and Neurodegenerative Diseases: Insights into the Regulatory Roles of SLC7A11
Wang, C., Liu, H., Xu, S., Deng, Y. L., Xu, B., Yang, T., & Liu, W. (2023) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-023-01343-7 · Cited by 63
Neuroregenerative Mechanisms of Allopregnanolone in Alzheimer’s Disease
Irwin, R. W., Wang, J. M., Chen, S., & Brinton, R. D. (2012) · Frontiers in Endocrinology · doi:10.3389/fendo.2011.00117 · Cited by 56
Wang, Q., Ning, L., Niu, Y., Liu, H., & Yao, X. (2014) · The Journal of Physical Chemistry B · doi:10.1021/jp507529f · Cited by 60
Silva, D. E. S., Cali, M. P., Pazin, W. M., Carlos-Lima, E., Trevisan, M. T. S., Venâncio, T., Arcísio-Miranda, M., Ito, A. S., & Carlos, R. M. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01130 · Cited by 59
Jayne, T., Newman, M., Verdile, G., Sutherland, G. T., Münch, G. W., Musgrave, I., Nik, S. H. M., & Lardelli, M. T. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-151186 · Cited by 56
“Nevertheless, during the past decade, the amyloid hypothesis has come under increasing criticism for a number of reasons including the lack of overt neuronal loss following deposition of human A in mouse brains [21] (although synaptic toxicity is apparent [22]) and the failure of therapeutic approaches based on reduct…”
BackgroundRole of Receptors in Relation to Plaques and Tangles in Alzheimer’s Disease Pathology
Sharma, K., Pradhan, S., Duffy, L. K., Yeasmin, S., Bhattarai, N., & Schulte, M. K. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222312987 · Cited by 60
“The main objective is either to reduce the production of Aβ peptide or enhance their removal from the brain and prevent their aggregation [16].”
BackgroundRecent advancement in therapeutic strategies for Alzheimer’s disease: Insights from clinical trials
Khan, T., Waseem, R., Shahid, M., Ansari, J., Ahanger, I. A., Hassan, M. I., & Islam, A. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.102113 · Cited by 62
Amyloid-Beta Disrupts Calcium and Redox Homeostasis in Brain Endothelial Cells
Fonseca, A. C. R. G., Moreira, P. I., Oliveira, C. R., Cardoso, S. M., Pinton, P., & Pereira, C. (2014) · Molecular Neurobiology · doi:10.1007/s12035-014-8740-7 · Cited by 59
“Several evidences show that accumulation of amyloid-beta (Aβ) occurs in the brain parenchyma and in the cerebrovasculature in Alzheimer’s disease (AD) and suggest that neurovascular dysfunction plays a major role in the neurodegenerative process and cognitive decline [1–5].”
BackgroundThe effect of oxysterols on the interaction of Alzheimer's amyloid beta with model membranes
Phan, H. T. T., Hata, T., Morita, M., Yoda, T., Hamada, T., Vestergaard, M. C. M., & Takagi, M. (2013) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2013.06.021 · Cited by 55
Socías, S. B., González‐Lizárraga, F., Ávila, C. L., Vera, C., Acuña, L., Sepulveda-Diaz, J. E., Bel, E. A. D., Raisman‐Vozari, R., & Chehín, R. N. (2017) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2017.12.002 · Cited by 59
Towards a better understanding of the cannabinoid-related orphan receptors GPR3, GPR6, and GPR12
Morales, P., Isawi, I. H., & Reggio, P. H. (2018) · Drug Metabolism Reviews · doi:10.1080/03602532.2018.1428616 · Cited by 64
“…are caused by the accumulation of proteinaceous aggregates composed of amyloid-b (Ab) peptides (mainly Ab1–42 but also Ab1–40 peptides), whereas the neurofibrillary tangles are caused by hyperphosphorylation of the microtubule-associated protein Tau (LaFerla et al. 2007; Karran et al. 2011).”
BackgroundGold Nanoparticles Mediate Improved Detection of β-amyloid Aggregates by Fluorescence
Jara-Guajardo, P., Cabrera, P., Célis, F., Soler, M., Berlanga, I., Parra‐Muñoz, N., Acosta, G., Alberício, F., Guzmán, F., Campos, M., et al. (2020) · Nanomaterials · doi:10.3390/nano10040690 · Cited by 55
“The accumulation of the amyloid beta peptide (Aβ) produced by proteolytic cleavages fro the amyloid precursor protein (APP) generates toxic aggregates that are a key factor involved in the dysfunction and loss of synapses and neurons, causing AD symptoms [3,4].”
BackgroundIron stored in ferritin is chemically reduced in the presence of aggregating Aβ(1-42)
Everett, J., Brooks, J., Lermyte, F., O’Connor, P. B., Sadler, P. J., Dobson, J., Collingwood, J. F., & Telling, N. D. (2020) · Scientific Reports · doi:10.1038/s41598-020-67117-z · Cited by 55
Recent Advances in the Rational Drug Design Based on Multi-target Ligands
Yang, T., Sui, X., Yu, B., Shen, Y., & Cong, H. (2020) · Current Medicinal Chemistry · doi:10.2174/0929867327666200102120652 · Cited by 62
Biel, D., Suárez‐Calvet, M., Hager, P., Rubinski, A., Dewenter, A., Steward, A., Roemer, S., Ewers, M., Haass, C., Brendel, M., et al. (2023) · EMBO Molecular Medicine · doi:10.15252/emmm.202216987 · Cited by 54
“…cascade hypothesis, A b accumulation triggers the subsequent development and spreading of hyperphosphorylated tau aggregates which is followed by neurode-generation, metabolic decline, and eventually dementia (Karran et al , 2011; La Joie et al , 2020; Haass & Selkoe, 2022; Strom et al , 2022).”
BackgroundPoon, C. H., Wong, S. T. N., Roy, J., Wang, Y., Chan, H. W. H., Steinbusch, H. W. M., Blokland, A., Temel, Y., Aquili, L., & Lim, L. W. (2023) · Cells · doi:10.3390/cells12050780 · Cited by 64
“It has been suggested that early pharmacological treatment during the prodromal phase of Alzheimer’s Disease (AD) might prevent amyloid from reaching levels that trigger downstream pathologies, preventing disease development and slowing down the progression in clinical settings [1].”
BackgroundNam, Y., Shin, S. J., Kumar, V., Won, J., Kim, S., & Moon, M. (2025) · Translational Neurodegeneration · doi:10.1186/s40035-025-00479-4 · Cited by 66
“Targeting Aβ aggregation has proven a clinically relevant approach, advancing AD treatment strategies [164, 165].”
Beyond pathology: APP, brain development and Alzheimer's disease
Soldano, A., & Hassan, B. A. (2014) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2014.02.003 · Cited by 54
“However, all of the molecules that reached clinical trials failed [8].”
BackgroundTeller, S., Tahirbegi, I. B., Mir, M., Samitier, J., & Soriano, J. (2015) · Scientific Reports · doi:10.1038/srep17261 · Cited by 64
Tau acts as a mediator forAlzheimer's disease‐related synaptic deficits
Liao, D., Miller, E. C., & Teravskis, P. J. (2014) · European Journal of Neuroscience · doi:10.1111/ejn.12504 · Cited by 53
“Although it is still controversial which species of Ab and tau are the main culprits for dementia in AD (see reviews by Karran et al., 2011; Wischik et al., 2013; Zahs & Ashe, 2013), as discussed earlier, recent studies favor the roles of soluble species of Ab and tau over its insoluble deposits in…”
BackgroundMurakami, K. (2014) · Bioscience, Biotechnology, and Biochemistry · doi:10.1080/09168451.2014.940275 · Cited by 53
“To date, anti-Aβ drugs have been developed; these are mainly divided into three strategies: (1) anti-aggregation and clearance, (2) secretase inhibitors, and (3) Aβ degradation activator.”
BackgroundAlzheimer’s Disease: An Overview of Major Hypotheses and Therapeutic Options in Nanotechnology
Agarwal, M., Alam, R., Haider, M. K., Malik, M. Z., & Kim, D.-K. (2020) · Nanomaterials · doi:10.3390/nano11010059 · Cited by 63
Meng, J., Li, Y., Camarillo, C., Yao, Y., Zhang, Y., Xu, C., & Jiang, L. (2014) · PLoS ONE · doi:10.1371/journal.pone.0085570 · Cited by 59
“Some scholars suggest that the current amyloid cascade hypothesis is still correct but that some modification is needed [4].”
BackgroundInfluentialAlgamal, M., Ahmed, R., Jafari, N., Ahsan, B., Ortega, J., & Melacini, G. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m117.792853 · Cited by 55
“The exact etiology of Alzheimer’s disease is not fully understood, but the amyloid cascade hypothesis rationalizes a critical subset of the molecular phenotypes linked to the pathology of Alzheimer’s disease (1).”
Aβ Oligomer Elimination Restores Cognition in Transgenic Alzheimer’s Mice with Full-blown Pathology
Schemmert, S., Schartmann, E., Zafiu, C., Kass, B., Hartwig, S., Lehr, S., Bannach, O., Langen, K., Shah, N., Kutzsche, J., et al. (2018) · Molecular Neurobiology · doi:10.1007/s12035-018-1209-3 · Cited by 44
“The pathological hallmarks of AD are neurofibrillary tangles, consisting of hyperphosphorylated tau protein, progressive neurodegeneration, and the accumulation of toxic amyloid-β (Aβ) species [1, 5].”
Importance of GPCR-Mediated Microglial Activation in Alzheimer’s Disease
Haque, M. E., Kim, I., Jakaria, M., Akther, M., & Choi, D. (2018) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2018.00258 · Cited by 59
“In the AD brain, accumulation of this misfolded Aβ has been demonstrated to induce neuroinflammation by binding with several microglial innate immune receptors, including G-Protein-Coupled Receptors (GPCRs), which were postulated to induce an inflammatory cascade known as the ‘‘amyloid cascade-inflammatory hypothesis…”
BackgroundMeng, L., Xin, G., Li, B., Li, D., Sun, X., Yan, T., Li, L., Shi, L., Cao, S., & Meng, X. (2018) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.8b05404 · Cited by 59
Amyloid-ß promotes neurotoxicity by Cdk5-induced p53 stabilization
Lapresa, R., Agulla, J., Sánchez‐Morán, I., Zamarreño, R., Prieto, E., Bolaños, J. P., & Almeida, Á. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.11.019 · Cited by 57
“According to the widely accepted amyloid cascade hypothesis, the accumulation of Aβ in the brain -derived from the proteolytic processing of the amyloid precursor protein-is a primary triggering factor of AD pathogenesis as it initiates a molecular cascade of effects leading to neurodegeneration and the subsequent cli…”
Dietary Patterns and Cognitive Decline: key features for prevention
Dominguez, L. J., Barbagallo, M., Muñoz-Garcia, M., Godos, J., & Martinez-Gonzalez, M. A. (2019) · Current Pharmaceutical Design · doi:10.2174/1381612825666190722110458 · Cited by 53
Wang, X., Deng, Y., Gao, Y.-M., Dong, Y., Wang, F., Guan, Z.-Z., Hong, W., & Qi, X. (2020) · Aging · doi:10.18632/aging.102640 · Cited by 57
Cho, H., Sharma, A. K., Zhang, Y., Gross, M. L., & Mirica, L. M. (2020) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.0c00114 · Cited by 59
Quantum Dots as A Theranostic Approach in Alzheimer’s Disease: A Systematic Review
Villalva, M. D., Agarwal, V., Ulanova, M., Sachdev, P. S., & Braidy, N. (2021) · Nanomedicine · doi:10.2217/nnm-2021-0104 · Cited by 53
Zolezzi, J. M., BastÃas-Candia, S., Santos, M. J., & Inestrosa, N. C. (2014) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2014.00176 · Cited by 52
“its accumulation and aggregation (Karran et al., 2011).”
BackgroundInfluentialBranch, T., Girvan, P., Barahona, M., & Ying, L. (2014) · Angewandte Chemie International Edition · doi:10.1002/anie.201408810 · Cited by 58
Crary, J. (2016) · Journal of Neurology and Neuromedicine · doi:10.29245/2572.942x/2016/6.1059 · Cited by 52
Kim, K., Lee, S. H., Choi, D. S., & Park, C. B. (2018) · Advanced Functional Materials · doi:10.1002/adfm.201802813 · Cited by 56
Guo, Q., Zheng, X., Yang, P., Pang, X., Qian, K., Wang, P., Xu, S., Sheng, D., Wang, L., Cao, J., et al. (2018) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2018.12.010 · Cited by 54
Nanomedicine in Alzheimer's disease: Amyloid beta targeting strategy
Tosi, G., Pederzoli, F., Belletti, D., Vandelli, M. A., Forni, F., Duskey, J. T., & Ruozi, B. (2019) · Progress in brain research · doi:10.1016/bs.pbr.2019.03.001 · Cited by 56
LVFFARK-PEG-Stabilized Black Phosphorus Nanosheets Potently Inhibit Amyloid-β Fibrillogenesis
Yang, J., Liu, W., Sun, Y. P., & Dong, X. (2020) · Langmuir · doi:10.1021/acs.langmuir.9b03612 · Cited by 52
O-Glycosylation Induces Amyloid-β To Form New Fibril Polymorphs Vulnerable for Degradation
Liu, D., Wei, Q., Xia, W., He, C., Zhang, Q., Huang, L., Wang, X., Sun, Y., Ma, Y., Zhang, X., et al. (2021) · Journal of the American Chemical Society · doi:10.1021/jacs.1c08607 · Cited by 55
Antila, S., Chilov, D., Nurmi, H. J., Li, Z., Näsi, A., Gotkiewicz, M., Sitnikova, V., Jäntti, H., Acosta, N., Koivisto, H., et al. (2024) · Nature Cardiovascular Research · doi:10.1038/s44161-024-00445-9 · Cited by 56
“The dLV area percentage and location were similar in the WT and APdE9 mice at both ages, indicating that the APdE9 Research on the production and elimination of Aβ aggregates has provided important clues on the molecular pathogenesis of AD 4,7 .”
A fin-loop-like structure in GPX4 underlies neuroprotection from ferroptosis
Lorenz, S., Wahida, A., Bostock, M. J., Seibt, T., Mourão, A., Levkina, A., Trümbach, D., Soudy, M., Emler, D., Rothammer, N., et al. (2025) · Cell · doi:10.1016/j.cell.2025.11.014 · Cited by 71
Cellular Prion Protein as a Therapeutic Target in Alzheimer's Disease
Laurén, J. (2013) · Journal of Alzheimer's Disease · doi:10.3233/jad-130950 · Cited by 51
“The failures in passive anti-A immunotherapy clinical trials have to a certain degree called the relevance of A as therapeutic target in AD into question [84, 85].”
BackgroundHung, V. W. S., Masoom, H., & Kerman, K. (2012) · Journal of Electroanalytical Chemistry · doi:10.1016/j.jelechem.2012.05.023 · Cited by 53
Caspase-6 activity in the CA1 region of the hippocampus induces age-dependent memory impairment
LeBlanc, A. C., Ramcharitar, J., Afonso, V. M., Hamel, É., Bennett, D. A., Pakavathkumar, P., & Albrecht, S. (2014) · Cell Death and Differentiation · doi:10.1038/cdd.2013.194 · Cited by 56
Pettersson, M., Stepan, A. F., Kauffman, G. W., & Johnson, D. S. (2013) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2013.821465 · Cited by 54
“Genetic evidence from mutations in PS1, PS2, and APP supports the amyloid cascade hypothesis and puts the spotlight on g-secretase as a potentially attractive target for a disease-modifying treatment for Alzheimer’s disease (AD) [2].”
BackgroundTin, G., Mohamed, T., Gondora, N., Beazely, M. A., & Rao, P. P. N. (2015) · MedChemComm · doi:10.1039/c5md00274e · Cited by 50
Calcium Signalling Toolkits in Astrocytes and Spatio-Temporal Progression of Alzheimer's Disease
Lim, D., J Rodríguez-Arellano, J., Parpura, V., Zorec, R., Zeidán-Chuliá, F., A. Genazzani, A., & Verkhratsky, A. (2016) · Current Alzheimer Research · doi:10.2174/1567205013666151116130104 · Cited by 52
Immune and myodegenerative pathomechanisms in inclusion body myositis
Keller, C. W., Schmidt, J., & Lünemann, J. D. (2017) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.419 · Cited by 65
Sacuiu, S. F. (2016) · Handbook of clinical neurology · doi:10.1016/b978-0-12-802973-2.00008-2 · Cited by 72
Neural functions of bisecting GlcNAc
Kizuka, Y., & Taniguchi, N. (2018) · Glycoconjugate Journal · doi:10.1007/s10719-018-9829-4 · Cited by 54
Assembly of α-synuclein aggregates on phospholipid bilayers
Lv, Z., Hashemi, M., Banerjee, S., Zagorski, K., Rochet, J., & Lyubchenko, Y. L. (2019) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2019.06.006 · Cited by 52
Ribeiro, V. T., de Souza, L. C., & Silva, A. C. S. E. (2019) · Protein and Peptide Letters · doi:10.2174/0929866527666191230103739 · Cited by 56
Ketogenic diets and Alzheimer’s disease
Lange, K. W., Lange, K. M., Makulska-Gertruda, E., Nakamura, Y., Reissmann, A., Kanaya, S., & Hauser, J. (2017) · Food Science and Human Wellness · doi:10.1016/j.fshw.2016.10.003 · Cited by 56
“The ccumulation of abnormally folded A and tau proteins in amyoid plaques and neuronal tangles, respectively, appear to be ausally associated with the neurodegeneration in AD [8].”
BackgroundHampel, H., Vergallo, A., Caraci, F., Cuello, A. C., Lemercier, P., Vellas, B., Giudici, K. V., Baldacci, F., Hänisch, B., Haberkamp, M., et al. (2021) · Neuropharmacology · doi:10.1016/j.neuropharm.2020.108081 · Cited by 50
Brendel, M., Jaworska, A., Herms, J., Trambauer, J., Rötzer, C., Gildehaus, F.-J., Carlsen, J., Cumming, P., Bylund, J., Luebbers, T., et al. (2015) · Molecular Psychiatry · doi:10.1038/mp.2015.74 · Cited by 50
Alzheimer's disease: which type of amyloid-preventing drug agents to employ?
Jang, H., Connelly, L. S., Arce, F. T., Ramachandran, S., Lal, R., Kagan, B. L., & Nussinov, R. (2013) · Physical Chemistry Chemical Physics · doi:10.1039/c3cp00017f · Cited by 54
Drug Repositioning: An Opportunity to Develop Novel Treatments for Alzheimer’s Disease
Corbett, A., Williams, G., & Ballard, C. (2013) · Pharmaceuticals · doi:10.3390/ph6101304 · Cited by 50
“several pivotal clinical trials is due to a number of factors, including the lack of breadth in molecular targets of new treatments, which have predominantly focussed on amyloid to elicit disease modification [2].”
BackgroundAmino Acid Metaclusters: Implications of Growth Trends on Peptide Self-Assembly and Structure
Do, T. D., de Almeida, N. E. C., LaPointe, N. E., Chamas, A., Feinstein, S. C., & Bowers, M. T. (2015) · Analytical Chemistry · doi:10.1021/acs.analchem.5b03454 · Cited by 56
Loss of stability and hydrophobicity of presenilin 1 mutations causing Alzheimer's disease
Somavarapu, A. K., & Kepp, K. P. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13535 · Cited by 53
Zhang, Q., Hu, X., Wang, W., & Yuan, Z. (2016) · Biomacromolecules · doi:10.1021/acs.biomac.5b01603 · Cited by 50
Zhang, J., Mei, J., Hu, X., He, X., & Tian, H. (2016) · Small · doi:10.1002/smll.201601470 · Cited by 50
Jiang, Q., Chen, S., Hu, C., Huang, P., Shen, H., & Zhao, W. (2016) · Molecular Medicine Reports · doi:10.3892/mmr.2016.5542 · Cited by 57
“In addition, the accumulation of A β peptides has been identified as a key step in the multiple pathogenic changes associated with neurodegeneration and dementia (54,55).”
Lanznaster, D., Mack, J. M., Coelho, V., Ganzella, M., Almeida, R. F., Dal-Cim, T. A., Hansel, G., Zimmer, E. R., Souza, D. O., Prediger, R. D., et al. (2016) · Molecular Neurobiology · doi:10.1007/s12035-016-0082-1 · Cited by 53
Wang, C., Shou, Y., Pan, J., Du, Y., Liu, C., & Wang, H. (2019) · Nutritional Neuroscience · doi:10.1080/1028415x.2017.1416942 · Cited by 50
Alzheimer Disease: Perspectives from Epidemiology and Genetics
Haines, J. L. (2018) · The Journal of Law Medicine & Ethics · doi:10.1177/1073110518804230 · Cited by 56
Timmers, T., Ossenkoppele, R., Wolters, E. E., Verfaillie, S. C. J., Visser, D., Golla, S. S. V., Barkhof, F., Scheltens, P., Boellaard, R., van der Flier, W. M., et al. (2019) · Alzheimer's Research & Therapy · doi:10.1186/s13195-019-0510-3 · Cited by 49
Effects of Cu(II) on the aggregation of amyloid-β
Weibull, M. G. M., Simonsen, S., Oksbjerg, C. R., Tiwari, M. K., & Hemmingsen, L. (2019) · JBIC Journal of Biological Inorganic Chemistry · doi:10.1007/s00775-019-01727-5 · Cited by 54
(2020) · International Review of Neurobiology · doi:10.1016/bs.irn.2020.03.018 · Cited by 50
Kaur, P., Khera, A., Alajangi, H. K., Sharma, A., Jaiswal, P. K., Singh, G., & Barnwal, R. P. (2022) · Molecular Neurobiology · doi:10.1007/s12035-022-03164-z · Cited by 59
Dynamics of protein aggregation and oligomer formation governed by secondary nucleation
Michaels, T. C. T., Lazell, H. W., Arosio, P., & Knowles, T. P. J. (2015) · The Journal of Chemical Physics · doi:10.1063/1.4927655 · Cited by 49
Interdisciplinary challenges and promising theranostic effects of nanoscience in Alzheimer's disease
Laurent, S., Ejtehadi, M. R., Rezaei, M., Kehoe, P. G., & Mahmoudi, M. (2012) · RSC Advances · doi:10.1039/c2ra01374f · Cited by 54
Ooi, L., Sidhu, K., Poljak, A., Sutherland, G., O’Connor, M. D., Sachdev, P., & Münch, G. (2013) · Journal of Neural Transmission · doi:10.1007/s00702-012-0839-2 · Cited by 48
Ning, R., Lei, Y., Liu, S., Wang, H., Zhang, R., Wang, W., Zhu, Y., Zhang, H., & Zhao, W. (2015) · Journal of Natural Products · doi:10.1021/acs.jnatprod.5b00234 · Cited by 50
McCarthy, F. P., Adetoba, A., Gill, C. A., Bramham, K., Bertolaccini, M. L., Burton, G. J., Girardi, G., Seed, P. T., Poston, L., & Chappell, L. C. (2016) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2016.04.041 · Cited by 49
“001) and women with SLE without nephritis (13 [11-17]; p=0.”
BackgroundHerbst-Robinson, K. J., Liu, L., James, M., Yao, Y., Xie, S. X., & Brunden, K. R. (2015) · Scientific Reports · doi:10.1038/srep18286 · Cited by 49
Metadata
- Authors
- Karran, E., Mercken, M., & Strooper, B. D.
- Affiliations
- Janssen (Belgium) (BE)
- Vlaams Instituut voor Biotechnologie (BE)
- Corresponding author
- Karran, Eric
- Venue
- Nature Reviews Drug Discovery
- Published
- 2011-08-19
- Volume
- 10
- Issue
- 9
- Pages
- 698-712
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2079749054
- Cited by
- 2,188
- References
- 157
- Citations by year
- 2026: 74 · 2025: 115 · 2024: 130 · 2023: 139 · 2022: 141 · 2021: 158 · 2020: 174 · 2019: 191 · 2018: 174 · 2017: 163 · 2016: 171 · 2015: 160 · 2014: 151 · 2013: 130 · 2012: 107
- FWCI
- 13.91
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Lirias (KU Leuven) (submittedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- amyloid hypothesis, Alzheimer's disease, amyloid-beta, amyloid-beta aggregation, amyloid-beta production, clinical trial design, phase III trial failure, drug development
- MeSH terms
- Alzheimer Disease, Animals, Brain Chemistry, Humans, Research Design, Amyloid beta-Peptides, Treatment Failure, Clinical Trials, Phase II as Topic, Clinical Trials, Phase III as Topic, Age of Onset, Disease Progression, Plaque, Amyloid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.